Table 3.
Analyses of prognostic factors for survival
| OS | PFS | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
| HR (95%CI) | P | HR (95%CI) | P | HR (95%CI) | P | HR (95%CI) | P | |
| Sex (female VS male) | 0.639 (0.222–1.835) | 0.405 | 1.284 (0.534–3.086) | 0.576 | ||||
| Age (per 1 point increase) | 1.027 (0.993–1.063) | 0.125 | 1.001 (0.972–1.030) | 0.953 | ||||
| Age group (≥ 65 VS < 65) | 2.467 (1.153–5.279) | 0.020 | 2.545 (1.113–5.823) | 0.027 | 1.507 (0.734–3.094) | 0.264 | ||
| ECOG PS (per 1 point increase) | 1.363 (0.664–2.802) | 0.399 | 1.679 (0.891–3.164) | 0.109 | ||||
| BCLC stage (C VS B) | 2.185 (0.829–5.756) | 0.114 | 1.922 (0.843–4.379) | 0.120 | ||||
| Tumor size (per 1 point increase) | 1.010 (1.003–1.017) | 0.003 | 1.010 (1.003–1.017) | 0.005 | 1.006 (1.000–1.012) | 0.052 | - | - |
| Tumor size (≥ 10 cm VS < 10 cm) | 2.200 (1.050–4.613) | 0.037 | - | - | 1.523 (0.803–2.890) | 0.198 | ||
| Tumor distribution (multiple VS single) | 2.190 (0.663–7.233) | 0.199 | 1.890 (0.668–5.344) | 0.230 | ||||
| Child–Pugh class (B VS A) | 1.927 (0.878–4.232) | 0.102 | 1.913 (0.965–3.791) | 0.063 | - | - | ||
| Extrahepatic metastases (Yes VS No) | 1.638 (0.796–3.367) | 0.180 | 1.412 (0.757–2.636) | 0.278 | ||||
| Macrovascular invasion (Yes VS No) | 2.533 (1.151–5.574) | 0.021 | - | - | 2.332 (1.174–4.632) | 0.016 | 2.193 (1.083–4.443) | 0.029 |
| Liver Cirrhosis (Yes VS No) | 0.444 (0.126–1.563) | 0.206 | 0.634 (0.218–1.843) | 0.402 | ||||
| Hepatitis B (Yes VS No) | 0.562 (0.210–1.504) | 0.251 | 0.965 (0.372–2.501) | 0.942 | ||||
| Co-treatment time (late combination VS early combination) | 0.200 (0.077–0.522) | 0.001 | 0.175 (0.060–0.509) | 0.001 | 0.310 (0.144–0.665) | 0.003 | 0.422 (0.184–0.967) | 0.041 |
| AFP (≥ 200 VS < 200) | 1.946 (0.892–4.244) | 0.094 | - | - | 1.846 (0.937–3.636) | 0.076 | - | - |
| RBC | 0.956 (0.599–1.526) | 0.956 | 0.880 (0.590–1.312) | 0.529 | ||||
| WBC | 0.941 (0.769–1.153) | 0.559 | 0.892 (0.740–1.075) | 0.229 | ||||
| Platelet | 1.004 (1.000–1.007) | 0.065 | - | - | 1.002 (0.999–1.006) | 0.169 | ||
| Hb | 0.993 (0.977–1.011) | 0.451 | 0.990 (0.976–1.005) | 0.189 | ||||
| Neutrophils | 1.018 (0.829–1.249) | 0.866 | 0.967 (0.803–1.166) | 0.728 | ||||
| Lymphocyte | 0.377 (0.166–0.854) | 0.019 | - | - | 0.410 (0.200–0.842) | 0.015 | - | - |
| NLR | 1.074 (0.916–1.259) | 0.379 | 1.078 (0.938–1.240) | 0.288 | ||||
| ALT | 1.004 (0.995–1.014) | 0.362 | 1.003 (0.996–1.010) | 0.372 | ||||
| AST | 1.004 (0.998–1.009) | 0.189 | 1.003 (0.999–1.008) | 0.130 | ||||
| TBIL | 1.006 (0.973–1.040) | 0.716 | 1.002 (0.971–1.034) | 0.901 | ||||
| ALP | 1.005 (1.002–1.008) | 0.002 | - | - | 1.004 (1.002–1.007) | 0.002 | 1.004 (1.001–1.007) | 0.017 |
| TBA | 0.994 (0.982–1.007) | 0.348 | 1.000 (0.994–1.006) | 0.948 | ||||
| ALB | 0.949 (0.884–1.018) | 0.142 | 0.948 (0.892–1.008) | 0.088 | - | - | ||
ECOG PS Eastern Cooperative Oncology Group Performance Status, BCLC Barcelona Clinic Liver Cancer, RBC red blood cell, Hb Hemoglobin, WBC white blood cell, NLR Neutrophils/ Lymphocyte, ALT Alanine aminotransferase, AST Aspartate aminotransferase, TBIL total bilirubin, ALP alkaline phosphatase, TBA total bile acid, ALB albumin, AFP alpha-fetoprotein
Early combination was defined as treatment with apatinib and camrelizumab after the first or second TACE. Late combination was defined as having had at least three times TACE before receiving treatment with apatinib and camrelizumab